NICE recommend the use of ibrutinib as an option for three separate indications:• Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation • Relapsed or refractory mantle cell lymphoma• Waldenstrom’s macroglobulinaemia (recommended for use in the Cancer Drugs Fund)